Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-916 in Early Alzheimer's Disease
2022-500691-59-00Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing ABBV-916 with Placebo (2 arms). Primary endpoint: Change from Baseline in brain amyloid plaque deposition at Week 24. Started Jul 2023; status: completed.
02
Drugs
ABBV-916
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2022-500691-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500691-59-00.